GlassScriptPhysician profile
Steven H Lin
NPI 1922338334
$1,573.37
in general payments reported to CMS, 2019-2025
25 companies · $66.65 in 2025
The $66.65 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $154 · 2021: $395 · 2023: $19.69 · 2024: $21.26 · 2025: $66.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.64 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $234.51 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $182.67 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $142.82 | 2019-2020 | |
| Bausch Health US, LLC | $124.51 | 2019 | |
| Amgen INC. | $92.34 | 2019 | |
| Pfizer INC. | $63.06 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $44.85 | 2019 | |
| Medtronic, INC. | $39.61 | 2021 | |
| Arbor Pharmaceuticals, INC. | $39.14 | 2019 | |
| Scilex Pharmaceuticals INC. | $36.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.49 | 2021 | |
| Allergan, INC. | $33.19 | 2020 | |
| Ge Healthcare | $23.79 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $23.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $22.03 | 2020 | |
| Genzyme Corporation | $21.94 | 2019 | |
| Strongbridge US INC. | $20.87 | 2020 | |
| Nevro Corp. | $20.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.69 | 2023 | Gammagard Liquid |
| Novartis Pharmaceuticals Corporation | $19.23 | 2019 | |
| Csl Behring | $16.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2019 | |
| Acorda Therapeutics, INC | $11.77 | 2019 | |
| Lilly USA, LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.